Education
About Us
Working with TipRanks
Follow Us
OSE Immunotherapeutics SA (DE:6OP)
FRANKFURT:6OP
6OP Stock Chart & Stats
€5.12
-€0.25(-3.50%)
At close: 4:00 PM EST
€5.12
-€0.25(-3.50%)
Day’s Range― - ―
52-Week Range€4.27 - €7.17
Previous CloseN/A
Volume0.00
Average Volume (3M)6.00
Market Cap
€97.89M
Enterprise Value€111.21M
Total Cash (Recent Filing)€41.59M
Total Debt (Recent Filing)€38.66M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Apr 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding22,463,263
10 Day Avg. Volume20
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)2.45
Price to Sales (P/S)2.24
P/FCF Ratio3.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Profitability ImprovementsThe significant improvement in net profit margin indicates enhanced profitability, suggesting that the company is managing costs effectively and improving its bottom line, which is crucial for long-term sustainability.
Operational EfficiencyThe improvement in EBIT and EBITDA margins reflects better operational efficiency, indicating that the company is effectively managing its operations to enhance profitability, which is a positive sign for future growth.
Reduced LeverageThe reduction in leverage, as shown by the decreased debt-to-equity ratio, enhances financial stability and reduces risk, providing the company with more flexibility to invest in growth opportunities.
Bears Say
Declining RevenueThe negative revenue growth rate is a concern as it indicates declining sales, which could impact the company's ability to sustain profitability and growth in the long term.
Negative Cash Flow GrowthNegative free cash flow growth suggests challenges in maintaining cash availability for reinvestment, which could hinder the company's ability to fund future projects and expansions.
Limited Asset GrowthThe lack of significant asset growth could limit the company's ability to expand its operations and invest in new opportunities, potentially affecting its competitive position in the market.
OSE Immunotherapeutics SA News
6OP FAQ
What was OSE Immunotherapeutics SA’s price range in the past 12 months?
OSE Immunotherapeutics SA lowest stock price was €4.27 and its highest was €7.17 in the past 12 months.
What is OSE Immunotherapeutics SA’s market cap?
OSE Immunotherapeutics SA’s market cap is €97.89M.
When is OSE Immunotherapeutics SA’s upcoming earnings report date?
OSE Immunotherapeutics SA’s upcoming earnings report date is Apr 01, 2026 which is in 43 days.
How were OSE Immunotherapeutics SA’s earnings last quarter?
OSE Immunotherapeutics SA released its earnings results on Oct 15, 2025. The company reported -€0.683 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.683.
Is OSE Immunotherapeutics SA overvalued?
According to Wall Street analysts OSE Immunotherapeutics SA’s price is currently Overvalued.
Does OSE Immunotherapeutics SA pay dividends?
OSE Immunotherapeutics SA does not currently pay dividends.
What is OSE Immunotherapeutics SA’s EPS estimate?
OSE Immunotherapeutics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OSE Immunotherapeutics SA have?
OSE Immunotherapeutics SA has 22,463,263 shares outstanding.
What happened to OSE Immunotherapeutics SA’s price movement after its last earnings report?
OSE Immunotherapeutics SA reported an EPS of -€0.683 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.44%.
Which hedge fund is a major shareholder of OSE Immunotherapeutics SA?
Currently, no hedge funds are holding shares in DE:6OP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
OSE Immunotherapeutics SA
OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus; BI 765063, which is in Phase I clinical trial to treat solid tumors; and BiCKI, a novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets to fight primary and secondary resistance mechanisms developed by cancers. The company's products also comprise OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis; and OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA is headquartered in Nantes, France.
Technical Analysis
Options Prices
Currently, No data available
---